Third, although the TIMP-1 showed promising results in DLBCL prognosis (Figs. 7 and 8), however, the capability of TIMP-1 to serve as the diagnostic biomarker might be limited to discriminate the DLBCL patients from healthy control and other disease patients which remain to be investigated in the future (supplemental Fig. S18A). This evidence concerns the gene TIMP1 and diffuse large B-cell lymphoma.